Pfizer EBITDA Margin 2012-2026 | PFE
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Pfizer (PFE) over the last 10 years. The current EBITDA margin for Pfizer as of March 31, 2026 is
Unlock Macrotrends Premium
Start 7-Day Free Trial
Pfizer EBITDA Margin Historical Data
Date
TTM Revenue
TTM EBITDA
EBITDA Margin
2025-09-30
$62.79B
$20.42B
32.52%
2025-06-30
$63.83B
$21.62B
33.86%
2025-03-31
$62.46B
$18.94B
30.33%
2024-12-31
$63.63B
$19.42B
30.53%
2024-09-30
$60.43B
$12.67B
20.96%
2024-06-30
$56.22B
$4.34B
7.72%
2024-03-31
$55.95B
$5.38B
9.61%
2023-12-31
$59.55B
$7.57B
12.71%
2023-09-30
$70.12B
$16.93B
24.15%
2023-06-30
$79.27B
$28.67B
36.17%
2023-03-31
$94.00B
$38.30B
40.74%
2022-12-31
$101.18B
$40.85B
40.38%
2022-09-30
$99.88B
$38.43B
38.48%
2022-06-30
$101.28B
$35.80B
35.34%
2022-03-31
$92.43B
$29.32B
31.72%
2021-12-31
$81.29B
$24.62B
30.29%
2021-09-30
$68.88B
$22.11B
32.10%
2021-06-30
$55.12B
$18.28B
33.16%
2021-03-31
$46.08B
$14.63B
31.76%
2020-12-31
$41.65B
$12.93B
31.05%
2020-09-30
$32.07B
$7.32B
22.83%
2020-06-30
$34.47B
$8.18B
23.72%
2020-03-31
$37.87B
$10.70B
28.25%
2019-12-31
$40.91B
$12.47B
30.47%
2019-09-30
$40.22B
$11.65B
28.98%
2019-06-30
$40.84B
$12.52B
30.66%
2019-03-31
$41.04B
$12.27B
29.89%
2018-12-31
$40.83B
$11.82B
28.96%
2018-09-30
$53.37B
$20.31B
38.06%
2018-06-30
$53.24B
$20.17B
37.87%
2018-03-31
$52.67B
$19.94B
37.86%
2017-12-31
$52.55B
$19.99B
38.04%
2017-09-30
$52.47B
$19.42B
37.00%
2017-06-30
$52.35B
$18.60B
35.54%
2017-03-31
$52.60B
$18.15B
34.51%
2016-12-31
$52.82B
$17.90B
33.89%
2016-09-30
$53.24B
$17.86B
33.53%
2016-06-30
$52.29B
$18.07B
34.56%
2016-03-31
$50.99B
$18.00B
35.30%
2015-12-31
$48.85B
$16.98B
34.76%
2015-09-30
$47.92B
$17.20B
35.89%
2015-06-30
$48.20B
$17.58B
36.47%
2015-03-31
$49.12B
$18.16B
36.97%
2014-12-31
$49.61B
$18.79B
37.87%
2014-09-30
$50.05B
$19.84B
39.64%
2014-06-30
$50.33B
$20.34B
40.41%
2014-03-31
$50.53B
$20.88B
41.32%
2013-12-31
$51.58B
$21.59B
41.86%
2013-09-30
$50.88B
$21.73B
42.71%
2013-06-30
$51.19B
$21.62B
42.24%
2013-03-31
$52.18B
$22.25B
42.64%
2012-12-31
$54.66B
$22.92B
41.93%
2012-09-30
$53.25B
$22.62B
42.49%
2012-06-30
$56.90B
$23.53B
41.35%
2012-03-31
$59.42B
$23.26B
39.14%
2011-12-31
$61.04B
$22.99B
37.67%
2011-09-30
$65.06B
$22.42B
34.45%
2011-06-30
$64.44B
$22.10B
34.30%
2011-03-31
$65.09B
$22.25B
34.18%
2010-12-31
$65.17B
$21.81B
33.47%
2010-09-30
$65.50B
$19.75B
30.16%
2010-06-30
$61.13B
$18.86B
30.86%
2010-03-31
$54.98B
$16.57B
30.15%
2009-12-31
$49.27B
$15.72B
31.90%
2009-09-30
$45.82B
$17.60B
38.40%
2009-06-30
$46.17B
$17.13B
37.11%
2009-03-31
$47.32B
$16.86B
35.63%
2008-12-31
$48.30B
$16.82B
34.82%
2008-09-30
$48.82B
$16.68B
34.16%
2008-06-30
$48.84B
$13.79B
28.23%
2008-03-31
$47.79B
$12.51B
26.17%
2007-12-31
$48.42B
$12.72B
26.27%
2007-09-30
$48.15B
$12.28B
25.50%
2007-06-30
$48.44B
$15.48B
31.96%
2007-03-31
$49.10B
$16.97B
34.57%
2006-12-31
$48.37B
$17.42B
36.01%
2006-09-30
$47.37B
$18.49B
39.03%
2006-06-30
$46.35B
$16.77B
36.17%
2006-03-31
$46.06B
$16.82B
36.53%
2005-12-31
$47.41B
$16.77B
35.38%
2005-09-30
$47.20B
$17.54B
37.15%
2005-06-30
$48.77B
$19.81B
40.62%
2005-03-31
$49.59B
$20.27B
40.87%
2004-12-31
$48.99B
$19.30B
39.40%
2004-09-30
$51.57B
$18.18B
35.26%
2004-06-30
$51.09B
$16.15B
31.62%
2004-03-31
$48.72B
$8.96B
18.39%
2003-12-31
$44.74B
$8.28B
18.51%
2003-09-30
$40.01B
$8.15B
20.38%
2003-06-30
$35.66B
$7.89B
22.12%
2003-03-31
$33.05B
$13.07B
39.55%
2002-12-31
$32.29B
$12.62B
39.08%
2002-09-30
$29.03B
$11.38B
39.21%
2002-06-30
$28.86B
$11.18B
38.73%
2002-03-31
$29.19B
$11.28B
38.65%
2001-12-31
$29.02B
$10.86B
37.42%
2001-09-30
$31.14B
$8.95B
28.74%
2001-06-30
$30.47B
$7.94B
26.06%
2001-03-31
$29.84B
$6.97B
23.34%
2000-12-31
$29.41B
$4.71B
16.00%
2000-09-30
$25.81B
$5.69B
22.05%
2000-06-30
$21.99B
$4.19B
19.07%
2000-03-31
$18.78B
$3.68B
19.61%
1999-12-31
$15.54B
$4.43B
28.50%
1999-09-30
$14.90B
$4.32B
29.00%
1999-06-30
$14.90B
$4.99B
33.48%
1999-03-31
$14.24B
$4.39B
30.84%
1998-12-31
$13.35B
$3.89B
29.18%
1998-09-30
$12.39B
$2.98B
24.05%
1998-06-30
$11.71B
$2.39B
20.43%
1998-03-31
$11.09B
$2.21B
19.93%
1997-12-31
$10.74B
$2.08B
19.40%
1997-09-30
$10.99B
$2.28B
20.78%
1997-06-30
$11.14B
$2.65B
23.79%
1997-03-31
$11.31B
$2.99B
26.39%
1996-12-31
$11.31B
$3.23B
28.60%
1996-09-30
$10.89B
$3.14B
28.80%
1996-06-30
$10.63B
$2.89B
27.20%
1996-03-31
$10.37B
$2.60B
25.12%
1995-12-31
$10.02B
$2.30B
22.94%
1995-09-30
$9.58B
$2.25B
23.53%
1995-06-30
$9.11B
$2.07B
22.71%
1995-03-31
$8.64B
$2.01B
23.30%
1994-12-31
$8.28B
$1.97B
23.83%
1994-09-30
$7.97B
$1.88B
23.54%
1994-06-30
$7.77B
$1.82B
23.39%
1994-03-31
$7.59B
$1.74B
22.95%
1993-12-31
$7.48B
$1.67B
22.27%
1993-09-30
$7.44B
$1.62B
21.73%
1993-06-30
$7.39B
$1.57B
21.26%
1993-03-31
$7.34B
$1.52B
20.75%
1992-12-31
$7.23B
$1.44B
19.96%
1992-09-30
$7.13B
$1.35B
18.88%
1992-06-30
$7.08B
$1.32B
18.61%
1992-03-31
$7.02B
$1.29B
18.39%
1991-12-31
$6.95B
$1.25B
18.04%
1991-09-30
$6.89B
$1.20B
17.49%
1991-06-30
$6.76B
$1.16B
17.17%
1991-03-31
$6.62B
$1.12B
16.95%
1990-12-31
$6.41B
$1.05B
16.45%
1990-09-30
$6.12B
$1.02B
16.60%
1990-06-30
$5.91B
$0.98B
16.60%
1990-03-31
$5.72B
$0.95B
16.61%
1989-12-31
$5.67B
$0.97B
17.07%
1989-09-30
$5.55B
$0.97B
17.44%
1989-06-30
$5.49B
$0.97B
17.69%
1989-03-31
$5.52B
$1.05B
19.05%
1988-12-31
$5.39B
$1.01B
18.77%
1988-09-30
$5.29B
$1.01B
19.01%
1988-06-30
$5.21B
$0.99B
19.03%
1988-03-31
$5.10B
$0.99B
19.40%
1987-12-31
$4.92B
$0.94B
19.11%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $153.074B
$62.579B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
